Relapsing-Remitting Multiple Sclerosis (MS) Market Research Report Information By Treatment (Immunomodulating Drugs, Nrf2 Activators, Interferons, Others), By Route of Administration (Oral, Intravenous) and By End-User (Hospitals, Clinics, Others) – Forecast to 2032

Table of Contents

1. EXECUTIVE SUMMARY

1.1. Market Attractiveness Analysis

1.1.1. Global Relapsing Remitting MS Market, by Treatment

1.1.2. Global Relapsing Remitting MS Market, by Route of Administration

1.1.3. Global Relapsing Remitting MS Market, by End User

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Data Mining

3.3. Secondary Research

3.4. Primary Research

3.5. Breakdown of Primary Respondents

3.6. Forecasting Techniques

3.7. Research Methodology for Market Size Estimation

3.8. Bottom-Up Approach

3.9. Top-Down Approach

3.10. Data Triangulation

3.11. Validation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Porter’s Five Forces Analysis

5.1.1. Bargaining Power of Suppliers

5.1.2. Bargaining Power of Buyers

5.1.3. Threat of New Entrants

5.1.4. Threat of Substitutes

5.1.5. Intensity of Rivalry

5.2. Value Chain Analysis

5.2.1. R&D and Designing

5.2.2. Manufacturing

5.2.3. Distribution & Sales

5.2.4. Post Sales Services

6. GLOBAL RELAPSING REMITTING MS MARKET, BY TREATMENT

6.1. Overview

6.2. Immunomodulating Drugs

Market Estimates & Forecast, by Region, 2023-2032

Market Estimates & Forecast, by Country, 2023-2032

6.3. Nrf2 Activators

Market Estimates & Forecast, by Region, 2023-2032

Market Estimates & Forecast, by Country, 2023-2032

6.4. Interferons

Market Estimates & Forecast, by Region, 2023-2032

Market Estimates & Forecast, by Country, 2023-2032

6.5. Others

Market Estimates & Forecast, by Region, 2023-2032

Market Estimates & Forecast, by Country, 2023-2032

7. GLOBAL RELAPSING REMITTING MS MARKET, BY ROUTE OF ADMINISTRATION

7.1. Overview

7.2. Oral

Market Estimates & Forecast, by Region, 2023-2032

Market Estimates & Forecast, by Country, 2023-2032

7.3. Intravenous

Market Estimates & Forecast, by Region, 2023-2032

Market Estimates & Forecast, by Country, 2023-2032

8. GLOBAL RELAPSING REMITTING MS MARKET, BY END USER

8.1. Overview

8.2. Hospitals

Market Estimates & Forecast, by Region, 2023-2032

Market Estimates & Forecast, by Country, 2023-2032

8.3. Clinics

Market Estimates & Forecast, by Region, 2023-2032

Market Estimates & Forecast, by Country, 2023-2032

8.4. Others

Market Estimates & Forecast, by Region, 2023-2032

Market Estimates & Forecast, by Country, 2023-2032

9. GLOBAL RELAPSING REMITTING MS MARKET, BY REGION

9.1. Overview

9.2. Americas

9.2.1. North America

9.2.1.1. US

9.2.1.2. Canada

9.2.2. Latin America

9.3. Europe

9.3.1. Western Europe

9.3.1.1. Germany

9.3.1.2. France

9.3.1.3. Italy

9.3.1.4. Spain

9.3.1.5. UK

9.3.1.6. Rest of Western Europe

9.3.2. Eastern Europe

9.4. Asia-Pacific

9.4.1. Japan

9.4.2. China

9.4.3. India

9.4.4. Australia

9.4.5. South Korea

9.4.6. Rest of Asia-Pacific

9.5. Middle East & Africa

9.5.1. Middle East

9.5.2. Africa

10. COMPANY LANDSCAPE

10.1. Overview

10.2. Competitor Dashboard

10.3. Major Growth Strategy in the Global Relapsing Remitting MS Market

10.4. Competitive Benchmarking

10.5. The Leading Player in terms of Number of Developments in the Global Relapsing Remitting MS Market

10.6. Key Developments & Growth Strategies

10.7. Major Players Financial Matrix & Market Ratio

11. COMPANY PROFILES

11.1. Biogen

11.1.1. Company Overview

11.1.2. Products/Services Offered

11.1.3. Financial Overview

11.1.4. Key Developments

11.1.5. SWOT Analysis

11.1.6. Key Strategies

11.2. Eisai Co., Ltd.

11.3. Glenmark Pharmaceuticals

11.4. Merck KGaA

11.5. Novartis AG

11.6. Sanofi Genzyme

11.7. Teva Pharmaceutical Industries Ltd.

11.8. Others

12. APPENDIX

12.1. References

12.2. Related Reports

LIST OF TABLES

TABLE 1 GLOBAL RELAPSING REMITTING MS MARKET SYNOPSIS, 2023-2032

TABLE 2 GLOBAL RELAPSING REMITTING MS MARKET ESTIMATES & FORECAST, 2023-2032(USD MILLION)

TABLE 3 GLOBAL RELAPSING REMITTING MS MARKET, BY TREATMENT, 2023-2032(USD MILLION)

TABLE 4 GLOBAL RELAPSING REMITTING MS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2032(USD MILLION)

TABLE 5 GLOBAL RELAPSING REMITTING MS MARKET, BY END USER, 2023-2032(USD MILLION)

TABLE 6 GLOBAL RELAPSING REMITTING MS MARKET, BY REGION, 2023-2032(USD MILLION)

TABLE 7 NORTH AMERICA: RELAPSING REMITTING MS MARKET, BY TREATMENT, 2023-2032(USD MILLION)

TABLE 8 NORTH AMERICA: RELAPSING REMITTING MS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2032(USD MILLION)

TABLE 9 NORTH AMERICA: RELAPSING REMITTING MS MARKET, BY END USER, 2023-2032(USD MILLION)

TABLE 10 US: RELAPSING REMITTING MS MARKET, BY TREATMENT, 2023-2032(USD MILLION)

TABLE 11 US: RELAPSING REMITTING MS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2032(USD MILLION)

TABLE 12 US: RELAPSING REMITTING MS MARKET, BY END USER, 2023-2032(USD MILLION)

TABLE 13 CANADA: RELAPSING REMITTING MS MARKET, BY TREATMENT, 2023-2032(USD MILLION)

TABLE 14 CANADA: RELAPSING REMITTING MS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2032(USD MILLION)

TABLE 15 CANADA: RELAPSING REMITTING MS MARKET, BY END USER, 2023-2032(USD MILLION)

TABLE 16 LATIN AMERICA: RELAPSING REMITTING MS MARKET, BY TREATMENT, 2023-2032(USD MILLION)

TABLE 17 LATIN AMERICA: RELAPSING REMITTING MS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2032(USD MILLION)

TABLE 18 LATIN AMERICA: RELAPSING REMITTING MS MARKET, BY END USER, 2023-2032(USD MILLION)

TABLE 19 EUROPE: RELAPSING REMITTING MS MARKET, BY TREATMENT, 2023-2032(USD MILLION)

TABLE 20 EUROPE: RELAPSING REMITTING MS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2032(USD MILLION)

TABLE 21 EUROPE: RELAPSING REMITTING MS MARKET, BY END USER, 2023-2032(USD MILLION)

TABLE 22 WESTERN EUROPE: RELAPSING REMITTING MS MARKET, BY TREATMENT, 2023-2032(USD MILLION)

TABLE 23 WESTERN EUROPE: RELAPSING REMITTING MS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2032(USD MILLION)

TABLE 24 WESTERN EUROPE: RELAPSING REMITTING MS MARKET, BY END USER, 2023-2032(USD MILLION)

TABLE 25 EASTERN EUROPE: RELAPSING REMITTING MS MARKET, BY TREATMENT, 2023-2032(USD MILLION)

TABLE 26 EASTERN EUROPE: RELAPSING REMITTING MS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2032(USD MILLION)

TABLE 27 EASTERN EUROPE: RELAPSING REMITTING MS MARKET, BY END USER, 2023-2032(USD MILLION)

TABLE 28 ASIA-PACIFIC: RELAPSING REMITTING MS MARKET, BY TREATMENT, 2023-2032(USD MILLION)

TABLE 29 ASIA-PACIFIC: RELAPSING REMITTING MS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2032(USD MILLION)

TABLE 30 ASIA-PACIFIC: RELAPSING REMITTING MS MARKET, BY END USER, 2023-2032(USD MILLION)

TABLE 31 MIDDLE EAST & AFRICA: RELAPSING REMITTING MS MARKET, BY TREATMENT, 2023-2032(USD MILLION)

TABLE 32 MIDDLE EAST & AFRICA: RELAPSING REMITTING MS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2032(USD MILLION)

TABLE 33 MIDDLE EAST & AFRICA: RELAPSING REMITTING MS MARKET, BY END USER, 2023-2032(USD MILLION)

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL RELAPSING REMITTING MS MARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL RELAPSING REMITTING MS MARKET

FIGURE 4 GLOBAL RELAPSING REMITTING MS MARKET SHARE, BY TREATMENT, 2023 (%)

FIGURE 5 GLOBAL RELAPSING REMITTING MS MARKET SHARE, BY ROUTE OF ADMINISTRATION, 2023 (%)

FIGURE 6 GLOBAL RELAPSING REMITTING MS MARKET SHARE, BY END USER, 2023 (%)

FIGURE 7 GLOBAL RELAPSING REMITTING MS MARKET SHARE, BY REGION, 2023 (%)

FIGURE 8 AMERICAS: RELAPSING REMITTING MS MARKET SHARE BY REGION, 2023 (%)

FIGURE 9 NORTH AMERICA: RELAPSING REMITTING MS MARKET SHARE, BY COUNTRY, 2023 (%)

FIGURE 10 EUROPE: RELAPSING REMITTING MS MARKET SHARE, BY REGION, 2023 (%)

FIGURE 11 WESTERN EUROPE: RELAPSING REMITTING MS MARKET SHARE, BY COUNTRY, 2023 (%)

FIGURE 12 ASIA-PACIFIC: RELAPSING REMITTING MS MARKET SHARE, BY COUNTRY, 2023 (%)

FIGURE 13 MIDDLE EAST & AFRICA: RELAPSING REMITTING MS MARKET SHARE, BY COUNTRY, 2023 (%)

FIGURE 14 GLOBAL RELAPSING REMITTING MS MARKET: COMPANY SHARE ANALYSIS, 2023 (%)

FIGURE 15 BIOGEN: KEY FINANCIALS

FIGURE 16 BIOGEN: SEGMENTAL REVENUE

FIGURE 17 BIOGEN: REGIONAL REVENUE

FIGURE 18 EISAI CO., LTD: KEY FINANCIALS

FIGURE 19 EISAI CO., LTD: SEGMENTAL REVENUE

FIGURE 20 EISAI CO., LTD: REGIONAL REVENUE

FIGURE 21 GLENMARK PHARMACEUTICALS: KEY FINANCIALS

FIGURE 22 GLENMARK PHARMACEUTICALS: SEGMENTAL REVENUE

FIGURE 23 GLENMARK PHARMACEUTICALS: REGIONAL REVENUE

FIGURE 24 MERCK KGAA: KEY FINANCIALS

FIGURE 25 MERCK KGAA: SEGMENTAL REVENUE

FIGURE 26 MERCK KGAA: REGIONAL REVENUE

FIGURE 27 NOVARTIS AG: KEY FINANCIALS

FIGURE 28 NOVARTIS AG: SEGMENTAL REVENUE

FIGURE 29 NOVARTIS AG: REGIONAL REVENUE

FIGURE 30 SANOFI GENZYME: KEY FINANCIALS

FIGURE 31 SANOFI GENZYME: SEGMENTAL REVENUE

FIGURE 32 SANOFI GENZYME: REGIONAL REVENUE

FIGURE 33 TEVA PHARMACEUTICAL INDUSTRIES LTD: KEY FINANCIALS

FIGURE 34 TEVA PHARMACEUTICAL INDUSTRIES LTD: SEGMENTAL REVENUE

FIGURE 35 TEVA PHARMACEUTICAL INDUSTRIES LTD: REGIONAL REVENUE